Company Active LTD

Company profile

Osler Diagnostics Limited

Osler Diagnostics

Lab-quality diagnostics for anyone, anywhere, at any time

CRN
10001467
Founded
2016
Age
10

Overview

Legal name
OSLER DIAGNOSTICS LIMITED
Region
South East England
Registered address
KING CHARLES HOUSE
PARK END STREET
OXFORD
ENGLAND
OX1 1JD
Insolvency history
No

Company events

Reference milestones and recent Companies House filing stream events.

6 events
24 Feb
2027

Confirmation statement due

Confirmation Due

Next confirmation statement due date

30 Sep
2026

Accounts due

Accounts Due

Next accounts due date

21 May
2026

Capital Allotment Shares

Capital

SH01 | Transaction MzUyMzA1NjcyMWFkaXF6a2N4 | Paper/PDF filed

Published 29 May 2026 01:46

10 Feb
2026

Confirmation statement filed

Confirmation

Last confirmation statement made up date

31 Dec
2024

Accounts filed

Accounts

Last accounts made up date

11 Feb
2016

Incorporated

Inception

Company registered at Companies House

Public funding

5 awards
First funded
2018
Funded years
2018, 2020, 2021, 2022
Age at first award
1 years

Projects

2022 Collaborative R&D Lead participant

High-sensitivity, low-cost point of care testing for infection to combat antimicrobial resistance by reducing over-prescription of antibiotics

1 Apr 2022 to 31 Mar 2024

Awarded
£597,097
Total cost £995,161

Antimicrobial resistance (AMR), is a healthcare emergency. It is estimated to cause 12,000 deaths in the UK and 700,000 globally, and is forecast by the WHO to cause 10 million annual deaths globally by 2050, with the same economic impact as the 2008-2009 global financial crisis. Whereas antibiotics must be prescribed to treats serious infections, the gro...

2021 Feasibility Studies Lead participant

High sensitivity multiplex testing with a novel cardiac biomarker for rapid triage of acute chest pain patients enabling healthcare efficiencies and improved patient outcomes

1 Oct 2021 to 31 Dec 2022

Awarded
£299,990
Total cost £499,984

Acute myocardial infarctions (AMI/heart attacks) are one of the most common causes of death throughout the developed world. Each year ~720,000 UK citizens attend an emergency department (ED) with acute chest pain (ACP), representing ~6% of ED visits. Whilst the majority will not be suffering an AMI, due to the life-threatening nature of these symptoms, al...

2020 Study Lead participant

An innovative universal point-of-care diagnostic platform delivering cost-effective, high-sensitivity and multiplexed testing targeting rapid detection and diagnosis of sepsis

1 Jun 2020 to 30 Nov 2021

Awarded
£299,935
Total cost £499,892

Sepsis, a dysregulated immune response to infection leading to organ failure, is the leading cause of preventable death in the UK. Annually there are ~250,000 sepsis cases resulting in 46,000 deaths at a cost of ~£1.5Bn to the NHS and ~£11Bn to the UK economy. Early detection and treatment of sepsis significantly improves patient outcomes, with \>50% redu...

2018 Collaborative R&D Lead participant

Development of a small, low-cost, accurate and rapid Point-of-Care diagnostic platform, with primary application to critical cardiovascular markers

1 Nov 2018 to 31 Jan 2020

Awarded
£701,384
Total cost £1,001,978

"We are developing the next generation of healthcare diagnostics. Our portable diagnostic device could be deployed in the hospital emergency department, ambulance, or doctor's office and be used to diagnose diseases in under 10 minutes, cheaply, accurately, and from a pinprick of blood; moreover, it could diagnose an ever-increasing range of diseases, and...

2018 Feasibility Studies Lead participant

Oxford Impedance Diagnostics - operationalising a disruptive Point of Care platform

1 Jan 2018 to 30 Jun 2018

Awarded
£104,113
Total cost £148,733

We are developing a point of care (POC) diagnostic device that can perform most of the tests a conventional laboratory does, but in a hand held device that can sit on a GPs desk. Not only small, the device will also be cheap, accurate, and comprehensive (as it can test for a huge range of conditions). With such a device, doctors could diagnose patients li...

Product types

Collaborative R&D Feasibility Studies Study